Lung Cancer

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.

An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.

If the FDA’s Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development.

Henry S. Park, MD, MPH, discusses key considerations when selecting an optimal treatment approach for patients with stage II and III non–small cell lung cancer.

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

FDA approvals in recent years have started to carve out a role for immunotherapy in the frontline treatment of patients with small cell lung cancer.

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and the advantages of continued antibody-drug conjugate development across all areas of lung cancer.

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.

The treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.

Edward B. Garon, MD, MS, describes research combining angiogenesis and PD-1/PD-L1 inhibition stemming from the phase 3 IMpower150 trial in patients with metastatic nonsquamous NSCLC.

A panel of distinguished experts discuss how detection of actionable mutations affect their treatment choices in non-small cell lung cancer.

David Spigel, MD, and David H. Harpole Jr, MD, describe when adjuvant therapy is recommended in early stage NSCLC and discuss data from recent clinical trials of adjuvant therapy.

Ana Baramidze, MD, provides background on the FDA approvals of cemiplimab in NSCLC, expands on key efficacy and safety data with cemiplimab from EMPOWER-Lung 3, and discusses the current treatment landscape for patients with advanced NSCLC.

Filippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

The FDA has approved pembrolizumab (Keytruda) as an adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA non–small cell lung cancer.

A panel of experts in the treatment of NSCLC discusses how they manage patients with stage IB disease.

David H. Harpole Jr, MD, a thoracic surgeon, details his workup approach and discussed molecular testing for patients who present with NSCLC.

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Perioperative treatment with the combination of toripalimab plus platinum-containing doublet chemotherapy, followed by toripalimab monotherapy as consolidation therapy after surgery, significantly extended event-free survival compared with chemotherapy plus placebo in patients with operable NSCLC.